Search research articles
Contact Us
Filters
Showing results (91-100 of 225) with videos related to
Page
of 23
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 17, 2013
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
G Francis, L Kappos, P O'Connor, et al.
Neurology
|
November 1, 1990
Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals
M Pette, K Fujita, B Kitze, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 6, 2011
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study
X Montalban, G Comi, P O'Connor, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
May 17, 2000
Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction
R Haselhorst, L Kappos, D Bilecen, et al.
Psychopathology
|
July 27, 2007
Disease variables and depression affecting the process of coping in families with a somatically ill parent
B Steck, A Grether, F Amsler, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 31, 2007
Fatigue in multiple sclerosis: relation to depression, physical impairment, personality and action control
I-K Penner, N Bechtel, C Raselli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 30, 2005
A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis
U Baumhackl, L Kappos, E W Radue, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 27, 2014
Relapses in patients treated with fingolimod after previous exposure to natalizumab
G Comi, R Gold, F Dahlke, et al.
Neurology
|
September 30, 2010
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial
P Grossman, L Kappos, H Gensicke, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 1, 1997
Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial
D Poehlau, J Federlein, T Postert, et al.
Page
of 23
Search research articles
Search
Showing results (91-100 of 225) with videos related to
Sort By:
Page
of 23
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 17, 2013
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
G Francis, L Kappos, P O'Connor, et al.
Neurology
|
November 1, 1990
Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals
M Pette, K Fujita, B Kitze, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 6, 2011
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study
X Montalban, G Comi, P O'Connor, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
May 17, 2000
Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction
R Haselhorst, L Kappos, D Bilecen, et al.
Psychopathology
|
July 27, 2007
Disease variables and depression affecting the process of coping in families with a somatically ill parent
B Steck, A Grether, F Amsler, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 31, 2007
Fatigue in multiple sclerosis: relation to depression, physical impairment, personality and action control
I-K Penner, N Bechtel, C Raselli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 30, 2005
A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis
U Baumhackl, L Kappos, E W Radue, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 27, 2014
Relapses in patients treated with fingolimod after previous exposure to natalizumab
G Comi, R Gold, F Dahlke, et al.
Neurology
|
September 30, 2010
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial
P Grossman, L Kappos, H Gensicke, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 1, 1997
Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial
D Poehlau, J Federlein, T Postert, et al.
Page
of 23